We recently received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for our Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer. David Berman, our Chief Development Officer, sat down for an episode of IR Insights to provide an overview of this innovative program and Moderna’s research in the cancer prevention vaccine space: modernatx.com/media-center/a…

Today, along with the University of Oxford, we announced that a Phase 1/2 study of mRNA-4194, our investigational cancer vaccine for Lynch syndrome, has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK. The trial is part of a scientific collaboration between Moderna and the University of Oxford to advance a novel mRNA approach to cancer prevention. Read more: feeds.issuerdirect.com/news-…

Earlier today, Moderna and Merck presented 5-year follow-up data for intismeran autogene in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel and Chief Development Officer David Berman about these results. modernatx.com/recapping-mode… #ASCO2026 #ASCO26

Today we announced detailed results from a planned five-year follow-up analysis of the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab), @Merck's anti-PD-1 therapy, in patients with high-risk melanoma (stage III/IV) following complete resection. These data will be presented today at the 2026 American Society of Clinical Oncology (@ASCO) Annual Meeting (May 29-June 2) and published simultaneously in ASCO’s Journal of Clinical Oncology. Read more: feeds.issuerdirect.com/news-…

Today we announced an expanded collaboration with @CEPIvaccines (Coalition for Epidemic Preparedness Innovations) to advance the development of a potential vaccine against Bundibugyo ebolavirus, a cause of Ebola virus disease for which there are currently no licensed vaccines indicated. Read more: feeds.issuerdirect.com/news-…

Early detection matters when it comes to melanoma. The American Academy of Dermatology recommends regularly checking your skin — including areas that are easy to miss, like your scalp, back, palms, soles, and between your toes. If you notice a mole or spot that looks different, changes, itches or bleeds, make an appointment with a board-certified dermatologist. Regular skin checks, sun protection, and avoiding tanning beds can all help support skin health. #MelanomaAwarenessMonth

Melanoma outcomes can improve significantly when the disease is identified in its earliest stages, with a 95% 5-year survival rate when caught early. Knowing your skin and paying attention to changes like new or evolving moles, spots, or bumps is important. Regular skin self-checks, annual dermatology visits, sun protection, and avoiding tanning beds can all help reduce risk and support earlier identification of melanoma, when it may be easier to treat. #MelanomaAwarenessMonth

We’re proud to be named #1 on @TIME's list of the World’s Most Impactful Companies. Moderna was built on the belief that mRNA could change medicine—and that belief continues to drive us forward. Today, our pipeline spans infectious diseases, oncology and rare diseases, with continued research and innovation shaping what comes next. As we continue to advance what's possible with mRNA, we remain focused on turning breakthrough science into real-world impact for patients, and delivering for people and communities around the globe. Read more: feeds.issuerdirect.com/news-…

Results were published in Clinical Infectious Diseases from a Phase 1/2 randomized, observer-blind study of our mRNA-1018 pandemic influenza vaccine candidates targeting H5 and H7 viruses, supporting continued development of mRNA-based pandemic influenza vaccines for preparedness. academic.oup.com/cid/advance…

Today we announced a publication in the New England Journal of Medicine (@NEJM) of the positive Phase 3 study results evaluating mRNA-1010, our vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from our Phase 3 study (P304) evaluating the relative vaccine efficacy of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. Read more: feeds.issuerdirect.com/news-…

Today, we reported financial results and provided business updates for the first quarter of 2026. Read more: feeds.issuerdirect.com/news-…

Today we announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, @CEPIvaccines and Moderna announced that CEPI will invest up to $54.3 million to help advance mRNA-1018 to licensure. Read more: feeds.issuerdirect.com/news-…

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2 in Chicago, IL. Read more about the presentation details: feeds.issuerdirect.com/news-…

Today we announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), our mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. Read more: feeds.issuerdirect.com/news-…

Earlier today, we presented data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, held from April 17-22, 2026. Watch our latest IR Insights video with Dr. David Berman, Moderna’s new Chief Development Officer, to learn more about the presentation and Dr. Berman’s journey to Moderna. Watch here: modernatx.com/en-US/irinsigh…

We announced today that we will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026. The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1 (TPS≥1%). Read more: feeds.issuerdirect.com/news-…

We announced today that we will present late-breaking oral presentations on revaccination data for both mRNA-1010, our investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), our mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026. Learn more: feeds.issuerdirect.com/news-… #ESCMIDGlobal2026